{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:37:46Z","timestamp":1792190266448,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10524-z","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T19:34:20Z","timestamp":1747856060000},"page":"1005-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Heart failure with preserved ejection fraction therapeutics: in search of the pillars"],"prefix":"10.1007","volume":"30","author":[{"given":"Abdelghani El","family":"Rafei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio A. M.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia O.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"10524_CR1","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145:e895\u2013e1032","journal-title":"Circulation"},{"key":"10524_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE (2023) Heart failure with preserved ejection fraction. J Am Coll Cardiol 81:1810\u20131834","journal-title":"J Am Coll Cardiol"},{"key":"10524_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"10524_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098","journal-title":"N Engl J Med"},{"key":"10524_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485","journal-title":"N Engl J Med"},{"key":"10524_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215\u2013225","journal-title":"Eur Heart J"},{"key":"10524_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","volume":"15","author":"K Yamamoto","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M (2013) Investigators obotJ-D. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Failure 15:110\u2013118","journal-title":"Eur J Heart Failure"},{"key":"10524_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","volume":"11","author":"SV Arnold","year":"2023","unstructured":"Arnold SV, Silverman DN, Gosch K et al (2023) Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction. JACC Heart Fail 11:893\u2013900","journal-title":"JACC Heart Fail"},{"key":"10524_CR9","doi-asserted-by":"publisher","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","volume":"2","author":"DN Silverman","year":"2019","unstructured":"Silverman DN, Plante TB, Infeld M et al (2019) Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Netw Open 2:e1916598","journal-title":"JAMA Netw Open"},{"key":"10524_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejhf.3383","volume":"27","author":"S Matsumoto","year":"2025","unstructured":"Matsumoto S, Henderson AD, Shen L et al (2025) Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. Eur J Heart Fail 27:124\u2013139","journal-title":"Eur J Heart Fail"},{"key":"10524_CR11","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","volume":"78","author":"P Palau","year":"2021","unstructured":"Palau P, Seller J, Dom\u00ednguez E et al (2021) Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 78:2042\u20132056","journal-title":"J Am Coll Cardiol"},{"key":"10524_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","volume":"9","author":"P Palau","year":"2024","unstructured":"Palau P, de la Espriella R, Seller J et al (2024) \u03b2-Blocker withdrawal and functional capacity improvement in patients with heart failure with preserved ejection fraction. JAMA Cardiol 9:392\u2013396","journal-title":"JAMA Cardiol"},{"key":"10524_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","volume":"8","author":"M Infeld","year":"2023","unstructured":"Infeld M, Wahlberg K, Cicero J et al (2023) Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial. JAMA Cardiology 8:213\u2013221","journal-title":"JAMA Cardiology"},{"key":"10524_CR14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609\u20131620","journal-title":"N Engl J Med"},{"key":"10524_CR15","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: executive summary. Circulation 128:1810\u20131852","journal-title":"Circulation"},{"key":"10524_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"key":"10524_CR17","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338\u20132345","journal-title":"Eur Heart J"},{"key":"10524_CR18","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456\u20132467","journal-title":"N Engl J Med"},{"key":"10524_CR19","first-page":"Cd012721","volume":"6","author":"N Martin","year":"2018","unstructured":"Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT (2018) Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 6:Cd012721","journal-title":"Cochrane Database Syst Rev"},{"key":"10524_CR20","doi-asserted-by":"publisher","first-page":"e003588","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","volume":"10","author":"IE Beldhuis","year":"2017","unstructured":"Beldhuis IE, Streng KW, Ter Maaten JM et al (2017) Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data. Circ Heart Fail 10:e003588","journal-title":"Circ Heart Fail"},{"key":"10524_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M et al (2020) Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141:352\u2013361","journal-title":"Circulation"},{"key":"10524_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ejhf.2750","volume":"25","author":"A Sinha","year":"2023","unstructured":"Sinha A, Patel RB (2023) Loop diuretic management after sacubitril\/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye? Eur J Heart Fail 25:95\u201397","journal-title":"Eur J Heart Fail"},{"key":"10524_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF et al (2023) Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 82:1\u201312","journal-title":"J Am Coll Cardiol"},{"key":"10524_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jamacardio.2023.3216","volume":"8","author":"AS Bhatt","year":"2023","unstructured":"Bhatt AS, Vaduganathan M, Claggett BL et al (2023) Health and economic evaluation of sacubitril-valsartan for heart failure management. JAMA Cardiol 8:1041\u20131048","journal-title":"JAMA Cardiol"},{"key":"10524_CR25","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","volume":"44","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL et al (2023) Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J 44:2982\u20132993","journal-title":"Eur Heart J"},{"key":"10524_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"PM Mottram","year":"2004","unstructured":"Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110:558\u2013565","journal-title":"Circulation"},{"key":"10524_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781\u2013791","journal-title":"JAMA"},{"key":"10524_CR28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail 17:634\u2013642","journal-title":"J Card Fail"},{"key":"10524_CR29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"10524_CR30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMe1401231","volume":"370","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, O\u2019Connor C (2014) Lessons from the TOPCAT trial. N Engl J Med 370:1453\u20131454","journal-title":"N Engl J Med"},{"key":"10524_CR31","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"Sd Denus","year":"2017","unstructured":"Denus Sd, O\u2019Meara E, Desai AS et al (2017) Spironolactone metabolites in TOPCAT \u2014 New insights into regional variation. N Engl J Med 376:1690\u20131692","journal-title":"N Engl J Med"},{"key":"10524_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455\u2013462","journal-title":"Eur Heart J"},{"key":"10524_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400:757\u2013767","journal-title":"Lancet"},{"key":"10524_CR34","doi-asserted-by":"publisher","first-page":"e2330754","DOI":"10.1001\/jamanetworkopen.2023.30754","volume":"6","author":"K Chen","year":"2023","unstructured":"Chen K, Nie Z, Shi R et al (2023) Time to benefit of sodium-glucose cotransporter-2 inhibitors among patients with heart failure. JAMA Netw Open 6:e2330754\u2013e2330754","journal-title":"JAMA Netw Open"},{"key":"10524_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus J, Voors AA, Collins SP et al (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 44:41\u201350","journal-title":"Eur Heart J"},{"key":"10524_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler J, Filippatos G, Jamal Siddiqi T et al (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation 145:184\u2013193","journal-title":"Circulation"},{"key":"10524_CR37","doi-asserted-by":"publisher","first-page":"e245135","DOI":"10.1001\/jamanetworkopen.2024.5135","volume":"7","author":"M Gao","year":"2024","unstructured":"Gao M, Bhatia K, Kapoor A et al (2024) SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Netw Open 7:e245135","journal-title":"JAMA Netw Open"},{"key":"10524_CR38","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"10524_CR39","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44:3627\u20133639","journal-title":"Eur Heart J"},{"issue":"1","key":"10524_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jamacardio.2024.4489","volume":"10","author":"M Abdel Jawad","year":"2024","unstructured":"Abdel Jawad M, Spertus JA, Ikeaba U et al (2024) Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiol 10(1):89\u201394","journal-title":"JAMA Cardiol"},{"key":"10524_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","volume":"8","author":"LP Cohen","year":"2023","unstructured":"Cohen LP, Isaza N, Hernandez I et al (2023) Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol 8:419\u2013428","journal-title":"JAMA Cardiol"},{"key":"10524_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","volume":"151","author":"KF Docherty","year":"2025","unstructured":"Docherty KF, Henderson AD, Jhund PS et al (2025) Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation 151:45\u201358","journal-title":"Circulation"},{"issue":"2","key":"10524_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jacc.2024.09.018","volume":"85","author":"M Vaduganathan","year":"2025","unstructured":"Vaduganathan M, Claggett BL, Desai AS et al (2025) Time to significant benefit of finerenone in patients with heart failure. J Am Coll Cardiol 85(2):199\u2013202","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10524_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","volume":"85","author":"AS Desai","year":"2025","unstructured":"Desai AS, Vaduganathan M, Claggett BL et al (2025) Finerenone in patients with a recent worsening heart failure event. J Am Coll Cardiol 85(2):106\u2013116","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10524_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","volume":"85","author":"FR Mc Causland","year":"2024","unstructured":"Mc Causland FR, Vaduganathan M, Claggett BL et al (2024) Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J Am Coll Cardiol 85(2):159\u2013168","journal-title":"J Am Coll Cardiol"},{"key":"10524_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","volume":"24","author":"AS Desai","year":"2018","unstructured":"Desai AS, Liu J, Pfeffer MA et al (2018) Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail 24:313\u2013320","journal-title":"J Card Fail"},{"key":"10524_CR47","first-page":"1979","volume":"12","author":"J Chang","year":"2024","unstructured":"Chang J, Ambrosy AP, Vardeny O, Spall HGCV, Mentz RJ, Sauer AJ (2024) Mineralocorticoid antagonism in heart failure. JACC: Heart Failure 12:1979\u20131993","journal-title":"JACC: Heart Failure"},{"key":"10524_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42:152\u2013161","journal-title":"Eur Heart J"},{"key":"10524_CR49","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD et al (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 404:1119\u20131131","journal-title":"Lancet"},{"key":"10524_CR50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jchf.2018.08.007","volume":"6","author":"DW Kitzman","year":"2018","unstructured":"Kitzman DW, Nicklas BJ (2018) Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF. JACC Heart Fail 6:1008\u20131010","journal-title":"JACC Heart Fail"},{"key":"10524_CR51","first-page":"28","volume":"12","author":"J Harrington","year":"2024","unstructured":"Harrington J, Felker GM, Lingvay I, Pagidipati NJ, Pandey A, McGuire DK (2024) Managing obesity in heart failure. JACC: Heart Failure 12:28\u201334","journal-title":"JACC: Heart Failure"},{"key":"10524_CR52","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson C, Kondo T, Jhund PS et al (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 43:4406\u20134417","journal-title":"Eur Heart J"},{"key":"10524_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084","journal-title":"N Engl J Med"},{"key":"10524_CR54","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232","journal-title":"N Engl J Med"},{"key":"10524_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","volume":"84","author":"MC Petrie","year":"2024","unstructured":"Petrie MC, Borlaug BA, Butler J et al (2024) Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program. J Am Coll Cardiol 84:27\u201340","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10524_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. New Eng J Med 392(5):427\u2013437","journal-title":"New Eng J Med"},{"key":"10524_CR57","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/ehjci\/jeae201","volume":"25","author":"A Peikert","year":"2024","unstructured":"Peikert A, Solomon SD (2024) Contemporary treatment options in heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging 25:1517\u20131524","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10524_CR58","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.122.059280","volume":"146","author":"S Rosch","year":"2022","unstructured":"Rosch S, Kresoja KP, Besler C et al (2022) Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation 146:506\u2013518","journal-title":"Circulation"},{"key":"10524_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ahj.2022.08.009","volume":"254","author":"EM Murray","year":"2022","unstructured":"Murray EM, Greene SJ, Rao VN et al (2022) Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: findings from ASCEND-HF. Am Heart J 254:112\u2013121","journal-title":"Am Heart J"},{"key":"10524_CR60","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah SJ, Katz DH, Selvaraj S et al (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131:269\u2013279","journal-title":"Circulation"},{"key":"10524_CR61","first-page":"1549","volume":"11","author":"A Alogna","year":"2023","unstructured":"Alogna A, Koepp KE, Sabbah M et al (2023) Interleukin-6 in patients with heart failure and preserved ejection fraction. JACC: Heart Failure 11:1549\u20131561","journal-title":"JACC: Heart Failure"},{"key":"10524_CR62","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","volume":"118","author":"NR Pugliese","year":"2022","unstructured":"Pugliese NR, Pellicori P, Filidei F et al (2022) Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res 118:3536\u20133555","journal-title":"Cardiovasc Res"},{"key":"10524_CR63","unstructured":"Docherty KF, McDowell K, Welsh P et al. Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin. JACC: Heart Failure"},{"key":"10524_CR64","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jchf.2022.09.013","volume":"10","author":"ME Canonico","year":"2022","unstructured":"Canonico ME, Hsia J, Cannon CP, Bonaca MP (2022) Uptake of newer guideline-directed therapies in heart failure patients with diabetes or chronic kidney disease. JACC Heart Fail 10:989\u2013991","journal-title":"JACC Heart Fail"},{"key":"10524_CR65","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling S, Doehner W, Evertz R et al (2024) Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J 45:3789\u20133800","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10524-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10524-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10524-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:53:53Z","timestamp":1757177633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10524-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["10524"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10524-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"2 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs Harrington, Bonaca and Canonico receive salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado, that receives or has received research grant\/consulting funding between August 2021 and present from: Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma, Alnylam Pharmaceuticals, Inc., Amgen Inc., Angionetics, Inc., Anthos Therapeutics, Array BioPharma, Inc., AstraZeneca and Affiliates, Atentiv LLC, Audentes Therapeutics, Inc., Bayer and Affiliates, Bristol-Meyers Squibb Company, Cambrian Biopharma, Inc., Cardiol Therapeutics Inc., CellResearch Corp., Cleerly Inc., Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EP Trading Co. Ltd., Epizon Pharma, Inc., Esperion Therapeutics, Inc., Everly Well, Inc., Exicon Consulting Pvt. Ltd., Faraday Pharmaceuticals, Inc., Foresee Pharmaceuticals Co. Ltd., Fortress Biotech, Inc., HDL Therapeutics Inc., HeartFlow Inc., Hummingbird Bioscience, Insmed Inc., Ionis Pharmaceuticals, Janssen and Affiliates, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc., Medimmune Ltd., Merck & Affiliates, Nectero Medical Inc., Novartis Pharmaceuticals Corp., Novo Nordisk, Inc., Osiris Therapeutics Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., Prairie Education and Research Cooperative, Prothena Biosciences Limited, Regeneron Pharmaceuticals, Inc., Regio Biosciences, Inc., Sanofi-Aventis Groupe, Silence Therapeutics PLC, Smith & Nephew plc, Stealth BioTherapeutics Inc., VarmX, Virta Health Corporation. Dr. Ambrosy has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (K23HL150159 and R01 AG091005), the American Heart Association (2nd Century Early Faculty Independence Award), The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Inc., Bayer, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Dr. Tavares reported receiving lecture fees from Novo Nordisk outside the submitted work. Dr. Vardeny has received research support through grants to her institution from AstraZeneca, Bayer, Cardurion, and consulting fees from AstraZeneca, Bayer, Cardior, Cytokinetics, Moderna, and Novo Nordisk. Drs Andrew P Ambrosy, Josephine L Harrington, and Mario Enrico Canonico are Editorial Board Members.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}